Your browser doesn't support javascript.
loading
Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD.
Seddighi, Sahba; Qi, Yue A; Brown, Anna-Leigh; Wilkins, Oscar G; Bereda, Colleen; Belair, Cedric; Zhang, Yong-Jie; Prudencio, Mercedes; Keuss, Matthew J; Khandeshi, Aditya; Pickles, Sarah; Kargbo-Hill, Sarah E; Hawrot, James; Ramos, Daniel M; Yuan, Hebao; Roberts, Jessica; Sacramento, Erika Kelmer; Shah, Syed I; Nalls, Mike A; Colón-Mercado, Jennifer M; Reyes, Joel F; Ryan, Veronica H; Nelson, Matthew P; Cook, Casey N; Li, Ziyi; Screven, Laurel; Kwan, Justin Y; Mehta, Puja R; Zanovello, Matteo; Hallegger, Martina; Shantaraman, Anantharaman; Ping, Lingyan; Koike, Yuka; Oskarsson, Björn; Staff, Nathan P; Duong, Duc M; Ahmed, Aisha; Secrier, Maria; Ule, Jernej; Jacobson, Steven; Reich, Daniel S; Rohrer, Jonathan D; Malaspina, Andrea; Dickson, Dennis W; Glass, Jonathan D; Ori, Alessandro; Seyfried, Nicholas T; Maragkakis, Manolis; Petrucelli, Leonard; Fratta, Pietro.
Affiliation
  • Seddighi S; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Qi YA; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Brown AL; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Wilkins OG; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Bereda C; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Belair C; Francis Crick Institute, London, UK.
  • Zhang YJ; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Prudencio M; Laboratory of Genetics and Genomics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Keuss MJ; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Khandeshi A; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Pickles S; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Kargbo-Hill SE; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Hawrot J; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Ramos DM; Laboratory of Genetics and Genomics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Yuan H; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Roberts J; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Sacramento EK; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Shah SI; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Nalls MA; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Colón-Mercado JM; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Reyes JF; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Ryan VH; Leibniz Institute on Aging, Fritz Lipmann Institute (FLI), Beutenbergstrasse 11, 07745 Jena, Germany.
  • Nelson MP; Data Tecnica International, Washington, DC, USA.
  • Cook CN; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Li Z; Data Tecnica International, Washington, DC, USA.
  • Screven L; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Kwan JY; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Mehta PR; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Zanovello M; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Hallegger M; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Shantaraman A; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Ping L; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Koike Y; Data Tecnica International, Washington, DC, USA.
  • Oskarsson B; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Staff NP; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Duong DM; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Ahmed A; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Secrier M; Francis Crick Institute, London, UK.
  • Ule J; UK Dementia Research Institute at King's College London, London, UK.
  • Jacobson S; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Reich DS; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Rohrer JD; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Malaspina A; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Dickson DW; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Glass JD; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Ori A; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Seyfried NT; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Maragkakis M; UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
  • Petrucelli L; Department of Genetics, Evolution and Environment, UCL Genetics Institute, UCL, London, UK.
  • Fratta P; Francis Crick Institute, London, UK.
Sci Transl Med ; 16(734): eadg7162, 2024 02 14.
Article in En | MEDLINE | ID: mdl-38277467
ABSTRACT
Functional loss of TDP-43, an RNA binding protein genetically and pathologically linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), leads to the inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote the degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. Here, we show that mRNA transcripts harboring cryptic exons generated de novo proteins in TDP-43-depleted human iPSC-derived neurons in vitro, and de novo peptides were found in cerebrospinal fluid (CSF) samples from patients with ALS or FTD. Using coordinated transcriptomic and proteomic studies of TDP-43-depleted human iPSC-derived neurons, we identified 65 peptides that mapped to 12 cryptic exons. Cryptic exons identified in TDP-43-depleted human iPSC-derived neurons were predictive of cryptic exons expressed in postmortem brain tissue from patients with TDP-43 proteinopathy. These cryptic exons produced transcript variants that generated de novo proteins. We found that the inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Last, we showed that 18 de novo peptides across 13 genes were present in CSF samples from patients with ALS/FTD spectrum disorders. The demonstration of cryptic exon translation suggests new mechanisms for ALS/FTD pathophysiology downstream of TDP-43 dysfunction and may provide a potential strategy to assay TDP-43 function in patient CSF.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Frontotemporal Dementia / Amyotrophic Lateral Sclerosis Limits: Humans Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Frontotemporal Dementia / Amyotrophic Lateral Sclerosis Limits: Humans Language: En Year: 2024 Type: Article